At a glance
ClinicalIndex Comparison RecordPhase 3Completed
Drug / intervention
Certolizumab pegol (CDP870)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Multicentre, Double Blind, Placebo-controlled, Parallel Group 52-week Study to Assess the Efficacy and Safety of 2 Dose Regimens of Lyophilised CDP870 as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms and Preventing Structural Damage in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate
In Brief
A Phase 3 clinical trial evaluating Certolizumab pegol (CDP870) for Rheumatoid Arthritis. Completed, across 76 sites in 13 countries.
Detailed Summary
Patients will be assigned to one of three treatment groups. Study medication is administered over a 52 week study duration.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesArgentina, Australia, Belgium, Bulgaria, Canada, Chile, Croatia, Czechia, Israel, Latvia, Russia, Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2005
First PostedSep 2005
Primary CompletionOct 2006
TodayJul 2026
First PostedSep 9, 2005
Enrollment StartFeb 1, 2005
Primary CompletionOct 1, 2006
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 20.8 years ago
Interventions
Certolizumab pegol (CDP870)drug